Company intelligence / Profile preview

Flexuspine

Pittsburgh, Pennsylvania, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

Flexuspine received FDA conditional approval to begin a feasibility study of its FSU device, the first approved clinical study for a total spine arthroplasty system in the U.S.[3]. The FSU system aims to replace an entire functional spinal unit as an alternative to traditional fusion surgery by restoring mobility. The company has started clinical trials and seeks European regulatory approval with ongoing pilot studies funded by recent investment rounds[3][4].

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

FSU Total Spine Arthroplasty System

Commercial

Indications: Lumbar degenerative disc disease, Lumbar spinal stenosis

Beyond the preview

Go deeper on Flexuspine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flexuspine.

Explore the full profile